Rabeprazole Sodium
Product Images NDC 50090-1424

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 50090-1424). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-01 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 01)

Chemical structure of rabeprazole sodium, showing its molecular arrangement with benzimidazole and pyridine rings, and associated sodium, sulfur, oxygen, and carbon atoms.*

FDA Label Image

Image-02 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 02)

A line graph comparing mean heartburn scores over a study period of 28 days for three groups: placebo, RAB 10 mg, and RAB 20 mg. The x-axis represents study days from -14 to 28, and the y-axis represents mean heartburn scores from 0 to 4, with score levels defined from none to very severe. The graph shows trends in heartburn severity for each treatment group over time.*

FDA Label Image

Image03 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 03)

A line graph depicting mean heartburn scores over a study period of 28 days for three groups: placebo, Rabeprazole sodium 10 mg, and Rabeprazole sodium 20 mg. The graph shows heartburn scores on the vertical axis from 0 (none) to 4 (very severe) and study days on the horizontal axis, including a baseline period before day 0. The plot compares the different treatments' effects on heartburn severity over time.*

FDA Label Image

Image-04 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 04)

A line chart comparing mean heartburn scores over 28 study days between a placebo group (n=58) and a RABEPRAZOLE SODIUM 20 mg group (n=59). The vertical axis shows mean scores from 0 (none) to 4 (very severe). The chart indicates heartburn severity trends for both groups before and after day 0.*

FDA Label Image

Image05 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 05)

A line graph comparing mean heartburn scores over a 28-day study period for two groups: placebo (n=58) and RAB 20 mg (n=59). The x-axis represents study days from -14 to 28, and the y-axis represents mean heartburn scores ranging from 0 (none) to 4 (very severe). Scores decrease over time in both groups, with the RAB group showing consistently lower scores after day 0.*

FDA Label Image

Label Image (Lbl500901424)

Label for Rabeprazole Sodium 20 mg release tablets by A-S Medication Solutions. The label includes the product NDC (50090-1424), lot number field, storage instruction to protect from moisture at 77 degrees Fahrenheit, and a quantity of 30 delayed-release tablets. Manufacturer and distributor details are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.